WO2017023020A1 - Method of manufacturing improved ertapenem injection - Google Patents

Method of manufacturing improved ertapenem injection Download PDF

Info

Publication number
WO2017023020A1
WO2017023020A1 PCT/KR2016/008307 KR2016008307W WO2017023020A1 WO 2017023020 A1 WO2017023020 A1 WO 2017023020A1 KR 2016008307 W KR2016008307 W KR 2016008307W WO 2017023020 A1 WO2017023020 A1 WO 2017023020A1
Authority
WO
WIPO (PCT)
Prior art keywords
ertapenem
coagulated
generated
organic solvent
solution
Prior art date
Application number
PCT/KR2016/008307
Other languages
French (fr)
Inventor
Maeng Sup Kim
Hee Kyoon Yoon
Wol Young Kim
Ji Young Jung
Original Assignee
Daewoong Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co., Ltd. filed Critical Daewoong Pharmaceutical Co., Ltd.
Publication of WO2017023020A1 publication Critical patent/WO2017023020A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Definitions

  • the present invention relates to a method of manufacturing an improved ertapenem injection.
  • Ertapenem is a carbapenem-based antibiotic, whose chemical (systematic) name is (4R, 5S, 6S)-3-[(3S,5S)-5-[(3-carboxylphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3,2,1]hept-2-ene-2-carboxylic acid, ertapenem monosodium is represented by Formula 1, and ertapenem trisodium is represented by Formula 2.
  • Ertapenem is a monosodium salt (Formula 1), which is prepared in a large batch, a low-crystalline solid, hygroscopic under an ambient condition, and unstable at room temperature and refrigeration temperatures. Since ertapenem monosodium is unstable at approximately -20 °C or more, a bulk compound needs to be stored at low temperatures (approximately -20 °C) to prevent decomposition into dimers or generation of a ring-opened polymer. However, even though an unstable ertapenem monosodium salt can be stored at a low temperature after mass production, it should be converted into a stable dosage form before being used as an antibiotic once a day for intravenous (IV) or intramuscular (IM) administration.
  • IV intravenous
  • IM intramuscular
  • the ertapenem monosodium salt that was converted into a stable ertapenem trisodium salt (Formula 2) for a lyophilized preparation is used in the form of an injection, and can be stored below 25 °C.
  • Patent Documents 1 and 2 lyophilizing methods with 10 or more steps for converting ertapenem monosodium into a stable ertapenem trisodium salt are disclosed.
  • Such a lyophilizing method needs special equipment such as lyophilizing equipment, and is complicated since the process includes 10 or more steps. Also, since the processing time is three or four days, in the case of ertapenem which becomes unstable due to heat and time, there is a high probability of generating impurities such as a ring-opened polymer and a dimer during the process.
  • crystallization methods including converting an ertapenem monosodium salt into a stable ertapenem trisodium salt, and dropwise adding a sterilized solution including a stable ertapenem trisodium salt into an organic solvent (reverse dropwise addition) are disclosed.
  • Such crystallization methods compared with a lyophilizing method, have a simple and short process, and thus are advantageous in quality and industrial application of ertapenem which becomes unstable due to heat and time.
  • these methods are inconvenient because, before a sterilized solution including ertapenem is dropped into an organic solvent, it is necessary to perform filtration for sterilization and cooling in advance.
  • these methods use an excessive amount of a crystallization solvent, and have low initial quality and stability.
  • the inventors had attempted to solve the problems of the lyophilizing method and crystallization method (reverse dropwise addition), and thus, developed a method of preparing a high-quality ertapenem injection having enhanced stability with a high yield by direct dropwise addition of an organic solvent into a stabilized ertapenem trisodium salt solution, and thereby completed the present invention.
  • the present invention is directed to providing a method of preparing an ertapenem injection having improved yield, quality and stability, compared with the conventional lyophilizing method and crystallization method (reverse dropwise addition).
  • the present invention provides a method of preparing an ertapenem injection, including:
  • a first step of preparing a stabilized ertapenem trisodium salt solution by adding an ertapenem monosodium salt to a mixed solution of a stabilizer and water;
  • the present invention relates to a method of preparing a high-quality ertapenem trisodium salt injection having improved stability with a high yield.
  • the crystallization method (direct dropwise addition) according to the present invention is a simple and short process because it does not need special lyophilizing equipment, compared with the lyophilizing method, and is a several-hour crystallization process and thus takes only one day, unlike the process with 10 or more steps, which takes 3 to 4 days, and therefore the crystallization method is advantageous to industrial application.
  • impurities generated by ertapenem becoming unstable due to heat and time are minimized and ertapenem having a high quality in content and purity can be obtained.
  • the method of the present invention is a simple process since an organic solvent is added dropwise without any previous process of filtration for sterilization and cooling. Also, the method of the present invention can obtain high-quality ertapenem with high content and purity and is improved in stability, and thus it is economical and advantageous in industrial application.
  • the crystallization method (direct dropwise addition) according to the present invention is a simple process, is effective in inhibiting the generation of impurities, and achieves a high quality, a high yield and improved stability, compared with the conventional technology.
  • FIG. 1 is a graph illustrating comparison (20 to 23 °C, 4 weeks, HPLC area%) of stability with respect to a control drug (lyophilizing method), ertapenem injections prepared by the respective methods of Comparative Examples 3 to 6 (crystallization methods, reverse dropwise addition) and Example 1 (the crystallization method of the present invention, direct dropwise addition).
  • the present invention relates to a first step of preparing a stabilized ertapenem trisodium salt solution by adding an ertapenem monosodium salt to a mixed solution of a stabilizer and water; and a second step of crystallizing an ertapenem trisodium salt by direct dropwise addition of a solvent into the stabilized ertapenem trisodium salt solution.
  • direct dropwise addition refers to a method for crystallization by dropwise addition of an antisolvent (solvent with low solubility) into a solution in which a target compound is dissolved.
  • reverse dropwise addition refers to a method for crystallization by dropwise addition of a solution in which a target compound is dissolved into an antisolvent (solvent having low solubility).
  • times the amount used herein may include all of weight/weight, weight/volume, and volume/weight.
  • a stabilized ertapenem trisodium salt solution is prepared by adding an ertapenem monosodium salt to a mixed solution of a stabilizer and water (first step).
  • the first step only uses distilled water, and may be performed at 0 to 25 °C at which the distilled water is not frozen and should be as low as possible.
  • the stabilizer may act on an amine of pyrrolidine of the ertapenem monosodium salt to decompose the pyrrolidine, thereby serving to prevent the generation of a by-product, resulting in the provision of a sodium salt which can be prepared into a trisodium salt.
  • the sodium salt may be sodium carbonate or sodium bicarbonate, but the present invention is not limited thereto.
  • the sodium salt after being stabilized with carbon dioxide, the sodium salt may be provided from an NaOH aqueous solution.
  • the stabilizer may be included at 0.01 to 0.5 parts by weight with respect to 1 part by weight of the ertapenem monosodium salt.
  • acidity may not be adjusted to pH 7.0 to 8.0, or a greater amount of bases are needed for acidity adjustment, and thus crystallization may not be performed, or the yield and quality may be degraded.
  • the acidity may be adjusted to pH 7.0 to 8.0 such that the ertapenem monosodium salt is converted into a trisodium salt.
  • the water used herein is a solvent for dissolving the ertapenem monosodium salt, and may be included at 2 to 7 parts by weight with respect to 1 part by weight of the ertapenem monosodium salt.
  • the ertapenem monosodium salt is not dissolved, and when too much water is used, the ertapenem monosodium salt is not crystallized.
  • the ertapenem trisodium salt is crystallized by direct dropwise addition of an organic solvent into the stabilized ertapenem trisodium salt solution prepared in the first step (the second step).
  • the ertapenem trisodium salt is crystallized by sequentially adding a first organic solvent and a second organic solvent to the stabilized ertapenem trisodium salt solution.
  • the first organic solvent may be methanol.
  • an organic solvent, other than methanol is dropped, crystals are not generated, or are not properly generated due to turbidity or coagulation.
  • the organic solvent used in the second dropping may be different from the first organic solvent, and specifically, one or more selected from the group consisting of ethanol, isopropylamine (IPA), 1-propanol, n-butanol, acetonitrile, acetone and tetrahydrofuran.
  • IPA isopropylamine
  • the total amount of the first and second organic solvents used herein may be 15 parts by volume to 25 parts by volume with respect to 1 part by volume of the water used in the preparation of the ertapenem trisodium salt solution.
  • the amount of the first organic solvent used herein may be more than 20/3 parts by volume to 12 parts by volume or less with respect to 1 part by volume of the water used in the preparation of the ertapenem trisodium salt solution, or more than 20 parts by weight to 35 parts by weight or less with respect to 1 part by weight of the ertapenem monosodium salt. Beyond the above ranges, crystals are not generated.
  • the amount of the second organic solvent used herein may be 10 parts by volume to 20 parts by volume with respect to 1 part by volume of the water used in the preparation of the ertapenem trisodium salt solution, or 30 parts by weight to 60 parts by weight with respect to 1 part by weight of the ertapenem monosodium salt. Beyond the above range, crystals may be coagulated or may not be generated.
  • the second step may be performed at -50 to 25 °C (preferably -30 to 10 °C) to generate crystals, and preferably obtain a high-yield and high-quality injection.
  • ertapenem Approximately 160 g of ertapenem was divided into 10 equal portions, and gradually added to the sodium bicarbonate solution along with a 2N NaOH solution for approximately 60 minutes to be completely dissolved.
  • a 2N sodium hydroxide solution was added to maintain the pH at the fixed point of approximately 7.8.
  • a bulk drug was added, and a batch weight was adjusted to have a final weight of 95% using WFI maintained at approximately 1 to 5 °C, thereby preparing a bulk drug-sodium bicarbonate solution.
  • the bulk drug-sodium bicarbonate solution was further stirred for 20 minutes, the molar ratio of sodium hydroxide to the bulk drug was approximately 0.93 through titration of the 2N sodium hydroxide.
  • the final weight of the batch was further stirred for approximately 5 minutes, and adjusted to a total of 100% using WFI cooled at approximately 1 to 5 °C.
  • the final drug adding and mixing time was approximately 102 minutes, and the final batch weight was approximately 888.0 g.
  • the solution was maintained in a temperature range from approximately 1 to 5 °C, and filtered using a 0.22 mm filter.
  • the filtered result was put into a 20 mL vial, and then the vial was frozen at approximately -70 °C. Lyophilizing equipment was operated according to the following cycle:
  • the ertapenem trisodium salt solution was dropped into the prepared organic solvent at 0 to 5 °C. Crystals were washed with IPA, filtered and then dried (yield: 80%, content: 81%, HPLC area%: 93.2%).
  • the ertapenem trisodium salt solution was dropped into the prepared organic solvent at 0 to 5 °C.
  • the resulting solution was stirred at 0 to 5 °C for 1 hour and filtered to obtain crystals, and then the crystals were dried (yield: 76%, content: 76.4%, HPLC area%: 92.4%).
  • the ertapenem trisodium salt solution was dropped into the prepared organic solvent at 0 to 5 °C.
  • the resulting solution was stirred at 0 to 5 °C for 1 hour and filtered to obtain crystals, and then the crystals were dried (yield: 90%, content: 78%, HPLC area%: 92.08%).
  • the ertapenem trisodium salt solution was dropped into the prepared organic solvent at 0 to 5 °C.
  • the resulting solution was stirred at 0 to 5 °C for 1 hour and filtered to obtain crystals, and then the crystals were dried (yield: 84%, content: 86%, HPLC area%: 93.78%).
  • the ertapenem trisodium salt solution was dropped into the prepared organic solvent at 0 to 5 °C.
  • the resulting solution was stirred at 0 to 5 °C for 1 hour and filtered to obtain crystals, and then the crystals were dried (yield: 70%, content: 87%, HPLC area%: 94.21%).
  • Comparative Example 7 Crystallization method (direct dropwise addition)-when MeOH was used as first organic solvent 20/3 times or less the distilled water (20 times or less the weight of the ertapenem monosodium salt)
  • the resulting product was stirred at 0 to 5 °C to crystallize (it was determined that no crystals were generated and that more than 200 ml (20 times the weight of the ertapenem monosodium salt) of MeOH should be used to obtain crystals).
  • Comparative Example 8 Crystallization method (direct dropwise addition)-when solvent other than MeOH , was used as first organic solvent
  • a solvent, other than MeOH was sterilized by filtration with a 0.22-micrometer filter, and first dropped into the ertapenem trisodium salt solution at 0 to 5 °C.
  • the solvent, other than MeOH was sterilized by filtration with a 0.22-micrometer filter, and secondarily dropped at 0 to 5 °C.
  • the resulting product was stirred at 0 to 5 °C to crystallize (it was determined that no crystals were generated and that crystals are generated by first dropping MeOH and secondarily dropping the same type of solvent used above).
  • a organic solvent[Table 4] was sterilized by filtration with a 0.22-micrometer filter, and first dropped into the ertapenem trisodium salt solution at 0 to 5 °C.
  • the same type of solvent used in the first dropping was sterilized by filtration with a 0.22-micrometer filter, and secondarily dropped at 0 to 5 °C.
  • the resulting product was stirred at 0 to 5 °C to crystallize (it was determined that no crystals were generated with only one type of the organic solvent).
  • Vials were respectively filled with 1 g of the control drug (lyophilizing method), the ertapenem injections prepared in Comparative Examples 3 to 6 (crystallization methods; reverse dropwise addition) and Example 1 (crystallization method of the present invention; direct dropwise addition), and stored at 20 to 23 °C.
  • HPLC area% was measured in 1, 2, 3, or 4-weeks, and the results are shown in Table 5 and FIG. 1.
  • Example 1 directly dropwise addition
  • Example 1 has an excellent initial quality, compared with the lyophilizing method and the crystallization method (reverse dropwise addition).
  • the stability of Example 1 is the same as or higher than that of the control drug, and higher than those of Comparative Examples 3 to 6 (reverse dropwise addition).
  • the injections prepared by the crystallization method had the lowest initial quality ranging from 92.08% to 93.78%, and the largest decrease in stability ranging from ⁇ 2.18% to 5.63%
  • the injection prepared by the crystallization method (direct dropwise addition) according to the present invention had the highest initial quality of 96.14% and a decrease in stability of ⁇ 0.42%.
  • the injection (control drug) prepared by the lyophilizing method had an initial quality of 94.74%, which is lower than that of the ertapenem prepared by the crystallization method of the present invention, and a decrease in stability of ⁇ 0.84%, which is similar to that of the ertapenem prepared by the crystallization method of the present invention.
  • the injection prepared by the crystallization method (direct dropwise addition) according to the present invention had the highest initial quality, and a similar stability to the injection prepared by the lyophilizing method, and the injections prepared by the crystallization method (reverse dropwise addition) had the lowest stability.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a method of preparing an improved ertapenem injection, and more particularly, to a method of preparing an ertapenem injection improved in yield, quality and stability by direct dropwise addition, compared with the conventional lyophilizing method and crystallization method (reverse dropwise addition). The crystallization method (direct dropwise addition) according to the present invention is a simple process and thus is effective in preventing the generation of impurities, and exhibits high quality and yield and improved stability because of a minimized use of an organic solvent.

Description

METHOD OF MANUFACTURING IMPROVED ERTAPENEM INJECTION
The present invention relates to a method of manufacturing an improved ertapenem injection.
Ertapenem is a carbapenem-based antibiotic, whose chemical (systematic) name is (4R, 5S, 6S)-3-[(3S,5S)-5-[(3-carboxylphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3,2,1]hept-2-ene-2-carboxylic acid, ertapenem monosodium is represented by Formula 1, and ertapenem trisodium is represented by Formula 2.
[Formula 1]
Figure PCTKR2016008307-appb-I000001
[Formula 2]
Figure PCTKR2016008307-appb-I000002
Ertapenem is a monosodium salt (Formula 1), which is prepared in a large batch, a low-crystalline solid, hygroscopic under an ambient condition, and unstable at room temperature and refrigeration temperatures. Since ertapenem monosodium is unstable at approximately -20 ℃ or more, a bulk compound needs to be stored at low temperatures (approximately -20 ℃) to prevent decomposition into dimers or generation of a ring-opened polymer. However, even though an unstable ertapenem monosodium salt can be stored at a low temperature after mass production, it should be converted into a stable dosage form before being used as an antibiotic once a day for intravenous (IV) or intramuscular (IM) administration.
Currently, the ertapenem monosodium salt that was converted into a stable ertapenem trisodium salt (Formula 2) for a lyophilized preparation is used in the form of an injection, and can be stored below 25 ℃.
In Patent Documents 1 and 2, lyophilizing methods with 10 or more steps for converting ertapenem monosodium into a stable ertapenem trisodium salt are disclosed. Such a lyophilizing method needs special equipment such as lyophilizing equipment, and is complicated since the process includes 10 or more steps. Also, since the processing time is three or four days, in the case of ertapenem which becomes unstable due to heat and time, there is a high probability of generating impurities such as a ring-opened polymer and a dimer during the process.
In Patent Documents 3 and 4, crystallization methods including converting an ertapenem monosodium salt into a stable ertapenem trisodium salt, and dropwise adding a sterilized solution including a stable ertapenem trisodium salt into an organic solvent (reverse dropwise addition) are disclosed. Such crystallization methods (reverse dropwise addition), compared with a lyophilizing method, have a simple and short process, and thus are advantageous in quality and industrial application of ertapenem which becomes unstable due to heat and time. However, these methods are inconvenient because, before a sterilized solution including ertapenem is dropped into an organic solvent, it is necessary to perform filtration for sterilization and cooling in advance. Also, compared with the lyophilizing method, these methods use an excessive amount of a crystallization solvent, and have low initial quality and stability.
Therefore, it is necessary to find a simple method of preparing high-quality and stable ertapenem with a high yield, which can minimize the generation of impurities, compared with the conventional lyophilizing method and crystallization method (reverse dropwise addition).
[Prior art documents]
[Patent Documents]
1: International unexamined Patent Application No. 2001/32172
2: U.S. Unexamined Patent Application No. 2011-172201
3: U.S. Patent No. 8293924
4: U.S. Patent No. 8691803
Therefore, the inventors had attempted to solve the problems of the lyophilizing method and crystallization method (reverse dropwise addition), and thus, developed a method of preparing a high-quality ertapenem injection having enhanced stability with a high yield by direct dropwise addition of an organic solvent into a stabilized ertapenem trisodium salt solution, and thereby completed the present invention.
Accordingly, the present invention is directed to providing a method of preparing an ertapenem injection having improved yield, quality and stability, compared with the conventional lyophilizing method and crystallization method (reverse dropwise addition).
As a means for solving the problem, the present invention provides a method of preparing an ertapenem injection, including:
a first step of preparing a stabilized ertapenem trisodium salt solution by adding an ertapenem monosodium salt to a mixed solution of a stabilizer and water; and
a second step of crystallizing an ertapenem trisodium salt by direct dropwise addition of a solvent into the stabilized ertapenem trisodium salt solution.
The present invention relates to a method of preparing a high-quality ertapenem trisodium salt injection having improved stability with a high yield.
The crystallization method (direct dropwise addition) according to the present invention is a simple and short process because it does not need special lyophilizing equipment, compared with the lyophilizing method, and is a several-hour crystallization process and thus takes only one day, unlike the process with 10 or more steps, which takes 3 to 4 days, and therefore the crystallization method is advantageous to industrial application. As a result, impurities generated by ertapenem becoming unstable due to heat and time are minimized and ertapenem having a high quality in content and purity can be obtained.
In addition, compared with the conventional crystallization method (reverse dropwise addition), the method of the present invention is a simple process since an organic solvent is added dropwise without any previous process of filtration for sterilization and cooling. Also, the method of the present invention can obtain high-quality ertapenem with high content and purity and is improved in stability, and thus it is economical and advantageous in industrial application.
As a result, the crystallization method (direct dropwise addition) according to the present invention is a simple process, is effective in inhibiting the generation of impurities, and achieves a high quality, a high yield and improved stability, compared with the conventional technology.
FIG. 1 is a graph illustrating comparison (20 to 23 ℃, 4 weeks, HPLC area%) of stability with respect to a control drug (lyophilizing method), ertapenem injections prepared by the respective methods of Comparative Examples 3 to 6 (crystallization methods, reverse dropwise addition) and Example 1 (the crystallization method of the present invention, direct dropwise addition).
The present invention relates to a first step of preparing a stabilized ertapenem trisodium salt solution by adding an ertapenem monosodium salt to a mixed solution of a stabilizer and water; and a second step of crystallizing an ertapenem trisodium salt by direct dropwise addition of a solvent into the stabilized ertapenem trisodium salt solution.
The term "direct dropwise addition" used herein refers to a method for crystallization by dropwise addition of an antisolvent (solvent with low solubility) into a solution in which a target compound is dissolved.
Also, the term "reverse dropwise addition" refers to a method for crystallization by dropwise addition of a solution in which a target compound is dissolved into an antisolvent (solvent having low solubility).
Also, the "times the amount" used herein may include all of weight/weight, weight/volume, and volume/weight.
Hereinafter, each step of the method of preparing an improved ertapenem injection according to the present invention will be described in detail.
First, a stabilized ertapenem trisodium salt solution is prepared by adding an ertapenem monosodium salt to a mixed solution of a stabilizer and water (first step).
The first step only uses distilled water, and may be performed at 0 to 25 ℃ at which the distilled water is not frozen and should be as low as possible. The stabilizer may act on an amine of pyrrolidine of the ertapenem monosodium salt to decompose the pyrrolidine, thereby serving to prevent the generation of a by-product, resulting in the provision of a sodium salt which can be prepared into a trisodium salt. Specifically, the sodium salt may be sodium carbonate or sodium bicarbonate, but the present invention is not limited thereto. Particularly, after being stabilized with carbon dioxide, the sodium salt may be provided from an NaOH aqueous solution.
In addition, the stabilizer may be included at 0.01 to 0.5 parts by weight with respect to 1 part by weight of the ertapenem monosodium salt. When the content of the stabilizer used herein is larger than the above range, acidity may not be adjusted to pH 7.0 to 8.0, or a greater amount of bases are needed for acidity adjustment, and thus crystallization may not be performed, or the yield and quality may be degraded.
In addition, in the first step, the acidity may be adjusted to pH 7.0 to 8.0 such that the ertapenem monosodium salt is converted into a trisodium salt.
Particularly, the water used herein is a solvent for dissolving the ertapenem monosodium salt, and may be included at 2 to 7 parts by weight with respect to 1 part by weight of the ertapenem monosodium salt. When too little water is used, the ertapenem monosodium salt is not dissolved, and when too much water is used, the ertapenem monosodium salt is not crystallized.
Subsequently, the ertapenem trisodium salt is crystallized by direct dropwise addition of an organic solvent into the stabilized ertapenem trisodium salt solution prepared in the first step (the second step).
In the second step, the ertapenem trisodium salt is crystallized by sequentially adding a first organic solvent and a second organic solvent to the stabilized ertapenem trisodium salt solution.
The first organic solvent may be methanol. When an organic solvent, other than methanol, is dropped, crystals are not generated, or are not properly generated due to turbidity or coagulation.
The organic solvent used in the second dropping may be different from the first organic solvent, and specifically, one or more selected from the group consisting of ethanol, isopropylamine (IPA), 1-propanol, n-butanol, acetonitrile, acetone and tetrahydrofuran.
The total amount of the first and second organic solvents used herein may be 15 parts by volume to 25 parts by volume with respect to 1 part by volume of the water used in the preparation of the ertapenem trisodium salt solution.
Specifically, the amount of the first organic solvent used herein may be more than 20/3 parts by volume to 12 parts by volume or less with respect to 1 part by volume of the water used in the preparation of the ertapenem trisodium salt solution, or more than 20 parts by weight to 35 parts by weight or less with respect to 1 part by weight of the ertapenem monosodium salt. Beyond the above ranges, crystals are not generated. In addition, the amount of the second organic solvent used herein may be 10 parts by volume to 20 parts by volume with respect to 1 part by volume of the water used in the preparation of the ertapenem trisodium salt solution, or 30 parts by weight to 60 parts by weight with respect to 1 part by weight of the ertapenem monosodium salt. Beyond the above range, crystals may be coagulated or may not be generated.
The second step (crystallization step) may be performed at -50 to 25 ℃ (preferably -30 to 10 ℃) to generate crystals, and preferably obtain a high-yield and high-quality injection.
From the ertapenem trisodium salt prepared through such steps, a stable and high quality injection can be prepared with a high yield.
Hereinafter, the present invention will be described in further detail with reference to examples according to the present invention, or the scope of the present invention is not limited by the following examples.
Comparative Example 1: Example 1 (lyophilizing method) of Patent Document 1 (WO 2001/32172)
20 g of sodium hydroxide NF pellets were mixed with 250 mL of water for injection (WFI) under ambient temperature and pressure to dissolve, thereby preparing a 2N NaOH solution. The resulting solution was charged into 400 mL (approximately 50% of the total batch volume) of WFI. Afterward, 28.0 g of sodium bicarbonate was dissolved in an agitator/reaction vessel, and the agitator/reaction vessel was maintained at approximately 1 to 5 ℃ and a pH of approximately 8.1 to 8.5.
Approximately 160 g of ertapenem was divided into 10 equal portions, and gradually added to the sodium bicarbonate solution along with a 2N NaOH solution for approximately 60 minutes to be completely dissolved. To reduce pH limitation, a 2N sodium hydroxide solution was added to maintain the pH at the fixed point of approximately 7.8. Subsequently, a bulk drug was added, and a batch weight was adjusted to have a final weight of 95% using WFI maintained at approximately 1 to 5 ℃, thereby preparing a bulk drug-sodium bicarbonate solution. While the bulk drug-sodium bicarbonate solution was further stirred for 20 minutes, the molar ratio of sodium hydroxide to the bulk drug was approximately 0.93 through titration of the 2N sodium hydroxide. The final weight of the batch was further stirred for approximately 5 minutes, and adjusted to a total of 100% using WFI cooled at approximately 1 to 5 ℃. The final drug adding and mixing time was approximately 102 minutes, and the final batch weight was approximately 888.0 g.
The solution was maintained in a temperature range from approximately 1 to 5 ℃, and filtered using a 0.22 mm filter.
The filtered result was put into a 20 mL vial, and then the vial was frozen at approximately -70 ℃. Lyophilizing equipment was operated according to the following cycle:
(a) precipitation at a shelf temperature of approximately -40 ℃ for approximately 2 hours;
(b) heating at a rate of approximately 0.5 ℃/min to a shelf temperature of approximately -20 ℃;
(c) maintaining a shelf temperature at approximately -20 ℃ under a pressure of approximately 80 mTorr for approximately 48 hours;
(d) heating at a rate of approximately 0.1 ℃/min to a shelf temperature of approximately 10 ℃;
(e) heating at a rate of 0.5 ℃/min to a shelf temperature of approximately 40 ℃;
(f) maintaining at approximately 40 ℃ under approximately 80 mTorr for approximately 3 hours;
(g) heating at a rate of approximately 0.5 ℃/min to a shelf temperature of approximately 60 ℃;
(h) maintaining at approximately 60 ℃ under approximately 80 mTorr for approximately 3 hours;
(i) cooling a shelf to an ambient temperature (approximately 20 to 30 ℃); and
(j) blocking with a plug under a partial vacuum of approximately 0.9 bar/700 Torr.
Finally, the vial, as a final dosage form, was removed from the lyophilizing equipment, thereby obtaining stabilized ertapenem (HPLC area%: 95.6%).
Comparative Example 2: Crystallization method (reverse dropwise addition)-H2O/IPA=7/150 (organic solvent: 21 times distilled water) of Patent Document 3 (US 8293924)
2.5 g of NaHCO3 was dissolved in 70 ml of distilled water. 15 g of an ertapenem monosodium salt was slowly dropped into the solution at 0 to 5 ℃ and adjusted to pH of 7.5 using an NaOH aqueous solution. The resulting solution was stirred with carbon and alumina, and then filtered. The filtered solution was sterilized by filtration with a 0.2-micrometer filter (preparation of ertapenem trisodium salt solution).
[Preparation of organic solvent]
1500 ml (100 times the weight of the ertapenem monosodium salt) of IPA was sterilized by filtration with an 0.2-micrometer filter, and cooled to 0 to 5 ℃, thereby preparing an organic solvent.
[Crystallization]
The ertapenem trisodium salt solution was dropped into the prepared organic solvent at 0 to 5 ℃. Crystals were washed with IPA, filtered and then dried (yield: 80%, content: 81%, HPLC area%: 93.2%).
Comparative example 3: Crystallization method (reverse dropwise addition)-H2O/IPA=3/75 (organic solvent: 25 times distilled water) of Patent Document 4 (US 8691803)
1.77g of NaHCO3 and 10 g of one equivalent of an ertapenem monosodium salt were slowly added to 30 ml (three times the weight of the ertapenem monosodium salt) of distilled water at 0 to 5 ℃, and adjusted to a pH of 7.0 to 8.0 using an NaOH aqueous solution. The resulting solution was sterilized by filtration with a 0.22-micrometer filter, thereby obtaining 51.5 ml of a sterilized solution (preparation of ertapenem trisodium salt solution).
[Preparation of organic solvent]
750 ml (75 times the weight of the ertapenem monosodium salt) of IPA was sterilized by filtration with a 0.2-micrometer filter and cooled to 0 to 5 ℃, thereby preparing an organic solvent.
[Crystallization]
The ertapenem trisodium salt solution was dropped into the prepared organic solvent at 0 to 5 ℃. The resulting solution was stirred at 0 to 5 ℃ for 1 hour and filtered to obtain crystals, and then the crystals were dried (yield: 76%, content: 76.4%, HPLC area%: 92.4%).
Comparative Example 4: Crystallization method (reverse dropwise addition)-H2O/MeOH/IPA=3/20/80 (organic solvent: approximately 33 times distilled water) of Patent Document 4 (US 8691803)
1.77 g of NaHCO3 and 10 g of one equivalent of an ertapenem monosodium salt were slowly added to 30ml (three times the weight of the ertapenem monosodium salt) of distilled water at 0 to 5 ℃, and adjusted to a pH of 7.0 to 8.0 using an NaOH aqueous solution. The resulting solution was sterilized by filtration with a 0.22-micrometer filter, thereby obtaining 51.5 ml of a sterilized solution (preparation of ertapenem trisodium salt solution).
[Preparation of organic solvent]
200 ml (20 times the weight of the ertapenem monosodium salt) of MeOH and 800 ml (80 times the weight of the ertapenem monosodium salt) of IPA were sterilized by filtration with a 0.22-micrometer filter and cooled to 0 to 5 ℃, thereby preparing an organic solvent.
[Crystallization]
The ertapenem trisodium salt solution was dropped into the prepared organic solvent at 0 to 5 ℃. The resulting solution was stirred at 0 to 5 ℃ for 1 hour and filtered to obtain crystals, and then the crystals were dried (yield: 90%, content: 78%, HPLC area%: 92.08%).
Comparative Example 5: Crystallization method (reverse dropwise addition)-H2O/MeOH/IPA/MA=3/25/50/50 (organic solvent: approximately 42 times distilled water) of Patent Document 4 (US 8691803)
1.77 g of NaHCO3 and 10 g of one equivalent of an ertapenem monosodium salt were slowly added to 30 ml (three times the weight of the ertapenem monosodium salt) of distilled water at 0 to 5 ℃, and adjusted to a pH of 7.0 to 8.0 using an NaOH aqueous solution. The resulting solution was sterilized by filtration with a 0.22-micrometer filter, thereby obtaining 51.5 ml of a sterilized solution (preparation of ertapenem trisodium salt solution).
[Preparation of organic solvent]
250 ml (25 times the weight of the ertapenem monosodium salt) of MeOH, 500 ml (50 times the weight of the ertapenem monosodium salt) of IPA, and 500 ml (50 times the weight of the ertapenem monosodium salt) of methyl acetate (MA) were sterilized by filtration with a 0.22-micrometer filter and cooled to 0 to 5 ℃, thereby preparing an organic solvent.
[Crystallization]
The ertapenem trisodium salt solution was dropped into the prepared organic solvent at 0 to 5 ℃. The resulting solution was stirred at 0 to 5 ℃ for 1 hour and filtered to obtain crystals, and then the crystals were dried (yield: 84%, content: 86%, HPLC area%: 93.78%).
Comparative Example 6: Crystallization method (reverse dropwise addition)-H2O/EtOH/MA=3/30/60 (organic solvent: approximately 30 times distilled water) of Patent Document 4 (US 8691803)
1.77 g of NaHCO3 and 10 g of one equivalent of an ertapenem monosodium salt were slowly added to 30 ml (three times the weight of the ertapenem monosodium salt) of distilled water at 0 to 5 ℃, and adjusted to a pH of 7.0 to 8.0 using an NaOH aqueous solution. The resulting solution was sterilized by filtration with a 0.22-micrometer filter, thereby obtaining 51.5 ml of a sterilized solution (preparation of ertapenem trisodium salt solution).
[Preparation of organic solvent]
300 ml (30 times the weight of the ertapenem monosodium salt) of EtOH and 600 ml (60 times the weight of the ertapenem monosodium salt) of MA were sterilized by filtration with a 0.22-micrometer filter and cooled to 0 to 5 ℃, thereby preparing an organic solvent.
[Crystallization]
The ertapenem trisodium salt solution was dropped into the prepared organic solvent at 0 to 5 ℃. The resulting solution was stirred at 0 to 5 ℃ for 1 hour and filtered to obtain crystals, and then the crystals were dried (yield: 70%, content: 87%, HPLC area%: 94.21%).
Example 1: Crystallization method (direct dropwise addition)-H2O/MeOH/IPA=3/30/40 (organic solvent: approximately 23 times distilled water)
1.77g of NaHCO3 was dissolved in 30 ml (three times the weight of the ertapenem monosodium salt) of distilled water at 0 to 5 ℃. 10 g of one equivalent of an ertapenem monosodium salt was divided into 10 portions, slowly added for 30 minutes, and adjusted to a pH of 7.0 to 8.0 using a 2N NaOH aqueous solution. The resulting solution was sterilized by filtration with a 0.22-micrometer filter, thereby obtaining 60 ml of a sterilized solution (preparation of stabilized ertapenem trisodium salt solution).
300 ml (30 times the weight of the ertapenem monosodium salt) of MeOH sterilized by filtration with a 0.22-micrometer filter was first dropped into the ertapenem trisodium salt solution at 0 to 5 ℃. In addition, 400 ml (40 times the weight of the ertapenem monosodium salt) of IPA was sterilized by filtration with a 0.22-micrometer filter, and then secondarily dropped at 0 to 5 ℃. The resulting product was cooled to -20 ℃, stirred for 4 hours and filtered to obtain crystals, and then the crystals were dried (yield: 85%, content: 101.5%, HPLC area%: 98.83%).
Example 2: Crystallization method (direct dropwise addition)-H2O/MeOH/IPA=4/30/54 (organic solvent: 21 times distilled water)
1.77g of NaHCO3 was dissolved in 40 ml (four times the weight of the ertapenem monosodium salt) of distilled water at 0 to 5 ℃. 10 g of one equivalent of an ertapenem monosodium salt was divided into 10 portions, slowly added for 30 minutes, and adjusted to a pH of 7.0 to 8.0 using a 2N NaOH aqueous solution. The resulting solution was sterilized by filtration with a 0.22-micrometer filter, thereby obtaining 60 ml of a sterilized solution (preparation of stabilized ertapenem trisodium salt solution).
300 ml (30 times the weight of the ertapenem monosodium salt) of MeOH sterilized by filtration with a 0.22-micrometer filter was first dropped into the ertapenem trisodium salt solution at 0 to 5 ℃. In addition, 540 ml (54 times the weight of the ertapenem monosodium salt) of IPA was sterilized by filtration with a 0.22-micrometer filter, and then secondarily dropped at 0 to 5 ℃. The resulting product was cooled to -20 ℃, stirred for 4 hours and filtered to obtain crystals, and then the crystals were dried (yield: 82%, content: 100.5%, HPLC area%: 98.30%).
Example 3: Crystallization method (direct dropwise addition)-H2O/MeOH/IPA=3/25/40 (organic solvent: approximately 22 times distilled water)
1.77g of NaHCO3 was dissolved in 30 ml (three times the weight of the ertapenem monosodium salt) of distilled water at 0 to 5 ℃. 10 g of one equivalent of an ertapenem monosodium salt was divided into 10 portions, slowly added for 30 minutes, and adjusted to a pH of 7.0 to 8.0 using a 2N NaOH aqueous solution. The resulting solution was sterilized by filtration with a 0.22-micrometer filter, thereby obtaining 50 ml of a sterilized solution (preparation of stabilized ertapenem trisodium salt solution).
250 ml (25 times the weight of the ertapenem monosodium salt) of MeOH sterilized by filtration with a 0.22-micrometer filter was first dropped into the ertapenem trisodium salt solution at 0 to 5 ℃. In addition, 400 ml (40 times the weight of the ertapenem monosodium salt) of IPA was sterilized by filtration with a 0.22-micrometer filter, and then secondarily dropped at 0 to 5 ℃. The resulting product was cooled to -20 ℃, stirred for 4 hours and filtered to obtain crystals, and then the crystals were dried (yield: 87%, content: 100.8%, HPLC area%: 98.40%).
Example 4: Crystallization method (direct dropwise addition)-H2O/MeOH/IPA=4/25/48 (organic solvent: approximately 18 times distilled water)
1.77g of NaHCO3 was dissolved in 40 ml (four times the weight of the ertapenem monosodium salt) of distilled water at 0 to 5 ℃. 10 g of one equivalent of an ertapenem monosodium salt was divided into 10 portions, slowly added for 30 minutes, and adjusted to a pH of 7.0 to 8.0 using a 2N NaOH aqueous solution. The resulting solution was sterilized by filtration with a 0.22-micrometer filter, thereby obtaining 60 ml of a sterilized solution (preparation of stabilized ertapenem trisodium salt solution).
250 ml (25 times the weight of the ertapenem monosodium salt) of MeOH sterilized by filtration with a 0.22-micrometer filter was first dropped into the ertapenem trisodium salt solution at 0 to 5 ℃. In addition, 480 ml (48 times the weight of the ertapenem monosodium salt) of IPA was sterilized by filtration with a 0.22-micrometer filter, and then secondarily dropped at 0 to 5 ℃. The resulting product was cooled to -20 ℃, stirred for 4 hours and filtered to obtain crystals, and then the crystals were dried (yield: 80%, content: 101.5%, HPLC area%: 98.80%).
Example 5: Crystallization method (direct dropwise addition)-H2O/MeOH/IPA=4/30/42 (organic solvent: approximately 18 times distilled water)
1.77g of NaHCO3 was dissolved in 40 ml (four times the weight of the ertapenem monosodium salt) of distilled water at 0 to 5 ℃. 10 g of one equivalent of an ertapenem monosodium salt was divided into 10 portions, slowly added for 30 minutes, and adjusted to a pH of 7.0 to 8.0 using a 2N NaOH aqueous solution. The resulting solution was sterilized by filtration with a 0.22-micrometer filter, thereby obtaining 60 ml of a sterilized solution (preparation of stabilized ertapenem trisodium salt solution).
300 ml (30 times the weight of the ertapenem monosodium salt) of MeOH sterilized by filtration with a 0.22-micrometer filter was first dropped into the ertapenem trisodium salt solution at 0 to 5 ℃. In addition, 420 ml (42 times the weight of the ertapenem monosodium salt) of IPA was sterilized by filtration with a 0.22-micrometer filter, and then secondarily dropped at 0 to 5 ℃. The resulting product was cooled to -20 ℃, stirred for 4 hours and filtered to obtain crystals, and then the crystals were dried (yield: 82%, content: 100.1%, HPLC area%: 98.90%).
Example 6: Crystallization method (direct dropwise addition)-H2O/ MeOH /1-PrOH=4/30/40 (organic solvent: 17.5 times distilled water)
1.77g of NaHCO3 was dissolved in 40 ml (four times the weight of the ertapenem monosodium salt) of distilled water at 0 to 5 ℃. 10 g of one equivalent of an ertapenem monosodium salt was divided into 10 portions, slowly added for 30 minutes, and adjusted to a pH of 7.0 to 8.0 using a 2N NaOH aqueous solution. The resulting solution was sterilized by filtration with a 0.22-micrometer filter, thereby obtaining 50 ml of a sterilized solution (preparation of stabilized ertapenem trisodium salt solution).
300 ml (30 times the weight of the ertapenem monosodium salt) of MeOH sterilized by filtration with a 0.22-micrometer filter was first dropped into the ertapenem trisodium salt solution at 0 to 5 ℃. In addition, 400 ml (40 times the weight of the ertapenem monosodium salt) of 1-PrOH was sterilized by filtration with a 0.22-micrometer filter, and then secondarily dropped at 0 to 5 ℃. The resulting product was cooled to -20 ℃, stirred for 4 hours and filtered to obtain crystals, and then the crystals were dried (yield: 88%, content: 101.4%, HPLC area%: 98.90%).
Example 7: Crystallization method (direct dropwise addition)-H2O/MeOH/IPA=4/30/40 (organic solvent: 17.5 times distilled water)
1.77g of NaHCO3 was dissolved in 40 ml (four times the weight of the ertapenem monosodium salt) of distilled water at 0 to 5 ℃. 10 g of one equivalent of an ertapenem monosodium salt was divided into 10 portions, slowly added for 30 minutes, and adjusted to a pH of 7.0 to 8.0 using a 2N NaOH aqueous solution. The resulting solution was sterilized by filtration with a 0.22-micrometer filter, thereby obtaining 50 ml of a sterilized solution (preparation of stabilized ertapenem trisodium salt solution).
300 ml (30 times the weight of the ertapenem monosodium salt) of MeOH sterilized by filtration with a 0.22-micrometer filter was first dropped into the ertapenem trisodium salt solution at 0 to 5 ℃. In addition, 400 ml (40 times the weight of the ertapenem monosodium salt) of IPA was sterilized by filtration with a 0.22-micrometer filter, and then secondarily dropped at 0 to 5 ℃. The resulting product was stirred for 4 hours at 0 to 5 ℃ and filtered to obtain crystals, and then the crystals were dried (yield: 80%, content: 100.2%, HPLC area%: 98.50%).
Test Method Patent Condition Yield Content HPLC area%
Comparative Example 1 (Merck) Lyophilizing method WO2001/32172 - - 100% 94.7~95.9%
Ranbaxy US2011/172201 - 100% - 97%
Comparative Example 2 (Orchid) Crystallization method (reverse dropwise addition) US8293924 H2O/IPA=7/150 (organic solvent: 21 times distilled water) 53%~80% 81% 93.2%
Comparative Example 3 (Savoir) US8691803 H2O/IPA=3/75 (organic solvent: 25 times distilled water) 76% 76.4% 92.4%
Comparative Example 4 (Savoir) H2O/MeOH/IPA=3/20/80 (organic solvent: approximately 33 times distilled water) 90% 78% 92.08%
Comparative Example 5 (Savoir) H2O/MeOH/IPA/MA=3/25/50/50 (organic solvent: approximately 42 times distilled water) 84% 86% 93.78%
Comparative Example 6 (Savoir) H2O/EtOH/MA=3/30/60 (organic solvent: approximately 30 times distilled water) 70% 87% 94.21%
Example 1 Crystallization method (direct dropwise addition) H2O/MeOH/IPA=3/30/40 (organic solvent: approximately 23 times distilled water) 85% 101.5% 98.83%
Example 2 H2O/MeOH/IPA=4/30/54 (organic solvent: 21 times distilled water) 82% 100.5% 98.30%
Example 3 H2O/MeOH/IPA=3/25/40 (organic solvent: approximately 22 times distilled water) 87% 100.80% 98.40%
Example 4 H2O/MeOH/IPA=4/25/48 (organic solvent: approximately 18 times distilled water) 80% 101.5% 98.80%
Example 5 H2O/MeOH/IPA=4/30/42 (organic solvent: approximately 18 times distilled water) 82% 100.1% 98.90%
Example 6 H2O/MeOH/1-PrOH=4/30/40 (organic solvent: 17.5 times distilled water) 88% 101.4% 98.90%
Example 7 H2O/MeOH/IPA=4/30/40 (organic solvent: 17.5 times distilled water) 80% 100.2% 98.50%
Comparative Example 7: Crystallization method (direct dropwise addition)-when MeOH was used as first organic solvent 20/3 times or less the distilled water (20 times or less the weight of the ertapenem monosodium salt)
1.77g of NaHCO3 was dissolved in 30 ml (three times the weight of the ertapenem monosodium salt) of distilled water at 0 to 5 ℃. 10 g of one equivalent of an ertapenem monosodium salt was divided into 10 portions, slowly added for 30 minutes, and adjusted to a pH of 7.0 to 8.0 using a 2N NaOH aqueous solution. The resulting solution was sterilized by filtration with a 0.22-micrometer filter, thereby obtaining 50 ml of a sterilized solution (preparation of stabilized ertapenem trisodium salt solution).
50 ml, 100 ml, or 200 ml (5, 10 or 20 times the weight of the ertapenem monosodium salt) of MeOH sterilized by filtration with a 0.22-micrometer filter was first dropped into the ertapenem trisodium salt solution at 0 to 5 ℃. In addition, a small amount of EtOH, 1-PrOH, IPA, or acetone was sterilized by filtration with a 0.22-micrometer filter, and then secondarily dropped at 0 to 5 ℃. The resulting product was stirred at 0 to 5 ℃ to crystallize (it was determined that no crystals were generated and that more than 200 ml (20 times the weight of the ertapenem monosodium salt) of MeOH should be used to obtain crystals).
Test for crystallization according to amount of MeOH used herein
H2O (v/wt ertapenem monosodium) MeOH (v/wt ertapenem monosodium) Organic solvent
Amount used (v/wt ertapenem monosodium) EtOH 1-PrOH IPA Acetone
3 5 5 turbid × Crystals (small amount) turbid
10 turbid turbid coagulated turbid
15 turbid coagulated coagulated turbid
20 turbid coagulated coagulated turbid
25 turbid coagulated coagulated turbid
30 turbid coagulated coagulated turbid
40 turbid coagulated coagulated turbid
50 turbid coagulated coagulated coagulated
60 turbid coagulated coagulated coagulated
70 (small amount) coagulated coagulated coagulated
80 (small amount) coagulated coagulated coagulated
90 coagulated coagulated coagulated coagulated
10 5 turbid turbid turbid turbid
10 turbid turbid coagulated turbid
15 turbid coagulated coagulated turbid
20 turbid coagulated coagulated turbid
25 turbid coagulated coagulated turbid
30 turbid coagulated coagulated turbid
40 turbid coagulated coagulated turbid
50 turbid coagulated coagulated coagulated
60 turbid coagulated coagulated coagulated
70 coagulated coagulated coagulated coagulated
20 5 turbid turbid turbid turbid
10 turbid turbid (small amount) turbid
15 turbid turbid coagulated turbid
20 turbid turbid coagulated turbid
25 turbid turbid coagulated turbid
30 turbid coagulated coagulated turbid
40 turbid coagulated coagulated turbid
50 turbid coagulated coagulated turbid
60 turbid coagulated coagulated coagulated
70 turbid coagulated coagulated coagulated
80 turbid coagulated coagulated coagulated
90 turbid coagulated coagulated coagulated
100 turbid coagulated coagulated coagulated
Comparative Example 8: Crystallization method (direct dropwise addition)-when solvent other than MeOH , was used as first organic solvent
1.77g of NaHCO3 was dissolved in 30 ml (three times the weight of the ertapenem monosodium salt) of distilled water at 0 to 5 ℃. 10 g of one equivalent of an ertapenem monosodium salt was divided into 10 portions, slowly added for 30 minutes, and adjusted to a pH of 7.0 to 8.0 using a 2N NaOH aqueous solution. The resulting solution was sterilized by filtration with a 0.22-micrometer filter, thereby obtaining 50 ml of a sterilized solution (preparation of stabilized ertapenem trisodium salt solution).
A solvent, other than MeOH, was sterilized by filtration with a 0.22-micrometer filter, and first dropped into the ertapenem trisodium salt solution at 0 to 5 ℃. In addition, the solvent, other than MeOH, was sterilized by filtration with a 0.22-micrometer filter, and secondarily dropped at 0 to 5 ℃. The resulting product was stirred at 0 to 5 ℃ to crystallize (it was determined that no crystals were generated and that crystals are generated by first dropping MeOH and secondarily dropping the same type of solvent used above).
Crystallization using solvents except MeOH
H2O (v/wt ertapenem monosodium) EtOH (v/wt ertapenem monosodium) Organic solvent
Amount used (v/wt ertapenem monosodium) EtOH 1-PrOH IPA Acetone
3 5 5 - not generated coagulated turbid
10 - turbid coagulated coagulated
15 - coagulated coagulated coagulated
H2O 1-PrOH Amount used EtOH 1-PrOH IPA Acetone
3 5 5 turbid - coagulated coagulated
10 coagulated - coagulated coagulated
H2O Acetone Amount used EtOH 1-PrOH IPA Acetone
3 5 5 not generated coagulated coagulated -
10 coagulated coagulated coagulated -
Comparative Example 9: Crystallization method (direct dropwise addition)-when one type of organic solvent was used
1.77g of NaHCO3 was dissolved in distilled water (3, 4, 5, 7 or 10 times the weight of the ertapenem monosodium salt) at 0 to 5 ℃. 10 g of one equivalent of an ertapenem monosodium salt was divided into 10 portions, slowly added for 30 minutes, and adjusted to a pH of 7.0 to 8.0 using a 2N NaOH aqueous solution. The resulting solution was sterilized by filtration with a 0.22-micrometer filter, thereby obtaining 50 ml of a sterilized solution (preparation of stabilized ertapenem trisodium salt solution).
A organic solvent[Table 4], was sterilized by filtration with a 0.22-micrometer filter, and first dropped into the ertapenem trisodium salt solution at 0 to 5 ℃. In addition, the same type of solvent used in the first dropping was sterilized by filtration with a 0.22-micrometer filter, and secondarily dropped at 0 to 5 ℃. The resulting product was stirred at 0 to 5 ℃ to crystallize (it was determined that no crystals were generated with only one type of the organic solvent).
H2O (v/wt ertapenem monosodium) Use amount of used organic solvent (v/wt ertapenem monosodium) MeOH EtOH 1-PrOH IPA THF AN Acetone
3 3 not generated not generated coagulated not generated not generated not generated not generated
6 not generated not generated not generated not generated not generated not generated
9 not generated coagulated coagulated coagulated not generated coagulated
12 (small amount) not generated
15 (small amount) not generated
4 3 not generated not generated not generated not generated not generated not generated not generated
6 not generated not generated coagulated not generated not generated not generated not generated
9 not generated not generated not generated not generated not generated not generated
12 not generated coagulated coagulated coagulated not generated coagulated
15 ○(small amount) not generated
5 3 not generated not generated not generated not generated not generated not generated not generated
6 not generated not generated not generated not generated not generated not generated not generated
9 not generated not generated coagulated not generated not generated not generated not generated
12 not generated coagulated coagulated coagulated not generated coagulated
15 ○(small amount) not generated
7 5 not generated not generated not generated not generated not generated not generated not generated
10 ○(small amount) ○(small amount) ○(small amount) (small amount) ○(small amount) ○(small amount) ○(small amount)
15 ○(small amount) ○(small amount) ○(small amount) ○(small amount) ○(small amount) layer separated ○(small amount)
20 ○(small amount) ○(small amount) ○(small amount) oil ○(small amount) oil
25 ○(small amount) ○(small amount) ○(small amount) ○(small amount)
30 ○(small amount) ○(small amount) ○(small amount) ○(small amount)
35 ○(small amount) oil oil ○(small amount)
40 oil oil
10 5 not generated not generated not generated not generated not generated not generated not generated
10 ○(small amount) ○(small amount) ○(small amount) ○(small amount) ○(small amount) ○(small amount) ○(small amount)
15 ○(small amount) ○(small amount) ○(small amount) ○(small amount) ○(small amount) layer separated ○(small amount)
20 ○(small amount) ○(small amount) ○(small amount) (small amount) ○(small amount) ○(small amount)
25 ○(small amount) ○(small amount) ○(small amount) oil ○(small amount) oil
30 ○(small amount) ○(small amount) ○(small amount) ○(small amount)
40 ○(small amount) ○(small amount) oil oil
50 ○(small amount) coagulated
100 ○(small amount)
Experimental Example: Stability test and evaluation
Vials were respectively filled with 1 g of the control drug (lyophilizing method), the ertapenem injections prepared in Comparative Examples 3 to 6 (crystallization methods; reverse dropwise addition) and Example 1 (crystallization method of the present invention; direct dropwise addition), and stored at 20 to 23 ℃. Here, HPLC area% was measured in 1, 2, 3, or 4-weeks, and the results are shown in Table 5 and FIG. 1.
Stability comparison (20~23 ℃, 4 weeks, HPLC area%)
Duration Control drug Crystallization method (direct dropwise addition) Crystallization method (reverse dropwise addition)
(Invanz. V2336) Example 1 Comparative Example 3 Comparative Example 4 Comparative Example 5 Comparative Example 6
0 94.74% 96.14% 92.30% 92.08% 93.78% 93.78%
1 week 94.02% 95.67% 90.94% 90.00% 91.98% 91.98%
2 weeks 94.19% 94.90% 89.58% 89.35% 90.64% 90.64%
3 weeks 94.05% 94.70% 89.90% 88.67% 90.40% 89.42%
4 weeks 93.90% 95.72% 90.12% 87.96% 90.21% 88.15%
Purity change △ △-0.84% △-0.42% △-2.18% △-4.12% △-3.57% △-5.63%
It was observed that Example 1 (direct dropwise addition) has an excellent initial quality, compared with the lyophilizing method and the crystallization method (reverse dropwise addition). In addition, it was confirmed that the stability of Example 1 is the same as or higher than that of the control drug, and higher than those of Comparative Examples 3 to 6 (reverse dropwise addition).
While the injections prepared by the crystallization method (reverse dropwise addition) had the lowest initial quality ranging from 92.08% to 93.78%, and the largest decrease in stability ranging from △2.18% to 5.63%, the injection prepared by the crystallization method (direct dropwise addition) according to the present invention had the highest initial quality of 96.14% and a decrease in stability of △0.42%. Also, it was seen that the injection (control drug) prepared by the lyophilizing method had an initial quality of 94.74%, which is lower than that of the ertapenem prepared by the crystallization method of the present invention, and a decrease in stability of △0.84%, which is similar to that of the ertapenem prepared by the crystallization method of the present invention. That is, it was seen that the injection prepared by the crystallization method (direct dropwise addition) according to the present invention had the highest initial quality, and a similar stability to the injection prepared by the lyophilizing method, and the injections prepared by the crystallization method (reverse dropwise addition) had the lowest stability.

Claims (13)

  1. A method of preparing an ertapenem injection, comprising:
    a first step of preparing a stabilized ertapenem trisodium salt solution by adding an ertapenem monosodium salt to a mixed solution of a stabilizer and water; and
    a second step of crystallizing an ertapenem trisodium salt by direct dropwise addition into the stabilized ertapenem trisodium salt solution.
  2. The method of claim 1, wherein the first step is performed at 0 to 25 ℃.
  3. The method of claim 1, wherein the stabilizer is sodium carbonate or sodium bicarbonate.
  4. The method of claim 1, wherein the stabilizer is included at 0.01 to 0.5 parts by weight with respect to 1 part by weight of the ertapenem monosodium salt.
  5. The method of claim 1, wherein the water is included at 2 to 7 parts by weight with respect to 1 part by weight of the ertapenem monosodium salt.
  6. The method of claim 1, wherein the first step is adjusted to a pH of 7.0 to 8.0.
  7. The method of claim 1, wherein the second step is crystallizing the ertapenem trisodium salt by sequentially adding a first organic solvent and a second organic solvent to the stabilized ertapenem trisodium salt solution.
  8. The method of claim 7, wherein the first organic solvent is methanol.
  9. The method of claim 7, wherein the second organic solvent is one or more selected from the group consisting of ethanol, isopropylamine (IPA), 1-propanol, n-butanol, acetonitrile, acetone and tetrahydrofuran.
  10. The method of claim 7, wherein the first organic solvent is used at more than 3/20 parts by volume to 12 parts by volume or less with respect to 1 part by volume of the water used in the preparation of the ertapenem trisodium salt solution.
  11. The method of claim 1, wherein the second organic solvent is used at 10 parts by volume to 20 parts by volume with respect to 1 part by volume of the water used in the preparation of the ertapenem trisodium salt solution.
  12. The method of claim 1, wherein the second step is performed at -50 ℃ to 25 ℃.
  13. The method of claim 1, wherein the second step is performed at -30 ℃ to 10 ℃.
PCT/KR2016/008307 2015-07-31 2016-07-28 Method of manufacturing improved ertapenem injection WO2017023020A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0108799 2015-07-31
KR1020150108799A KR20170014842A (en) 2015-07-31 2015-07-31 Manufacuring method of improved ertapenem injection

Publications (1)

Publication Number Publication Date
WO2017023020A1 true WO2017023020A1 (en) 2017-02-09

Family

ID=57943263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/008307 WO2017023020A1 (en) 2015-07-31 2016-07-28 Method of manufacturing improved ertapenem injection

Country Status (2)

Country Link
KR (1) KR20170014842A (en)
WO (1) WO2017023020A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026572A2 (en) * 2001-09-26 2003-04-03 Merck & Co., Inc. Crystalline forms of ertapenem sodium
US20120190842A1 (en) * 2011-01-24 2012-07-26 Savior Lifetec Corporation Process for the preparation of antibiotic compounds
CN103127097A (en) * 2011-11-30 2013-06-05 上海医药工业研究院 Ertapenem pharmaceutical composition
US20130281427A1 (en) * 2010-12-31 2013-10-24 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Crystalline form of ertapenem sodium and preparation method therefor
CN103860485A (en) * 2012-12-18 2014-06-18 深圳市海滨制药有限公司 Ertapenem sodium freeze-dried preparation and preparing method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032172A1 (en) 1999-10-29 2001-05-10 Merck & Co., Inc. Process for formulation of carbapenem antibiotic compositions
EP2209787A4 (en) 2007-10-08 2011-08-03 Orchid Chemicals & Pharm Ltd Process for the preparation of carbapenem antibiotic
EP2505191A1 (en) 2008-06-11 2012-10-03 Ranbaxy Laboratories Limited Lyophilized Carbapenem antibiotic composition
US8691803B2 (en) 2011-01-24 2014-04-08 Savior Lifetec Corporation Process for the preparation of antibiotic compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026572A2 (en) * 2001-09-26 2003-04-03 Merck & Co., Inc. Crystalline forms of ertapenem sodium
US20130281427A1 (en) * 2010-12-31 2013-10-24 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Crystalline form of ertapenem sodium and preparation method therefor
US20120190842A1 (en) * 2011-01-24 2012-07-26 Savior Lifetec Corporation Process for the preparation of antibiotic compounds
CN103127097A (en) * 2011-11-30 2013-06-05 上海医药工业研究院 Ertapenem pharmaceutical composition
CN103860485A (en) * 2012-12-18 2014-06-18 深圳市海滨制药有限公司 Ertapenem sodium freeze-dried preparation and preparing method thereof

Also Published As

Publication number Publication date
KR20170014842A (en) 2017-02-08

Similar Documents

Publication Publication Date Title
WO2011071314A2 (en) Processes for preparing crystalline forms a and b of ilaprazole and process for converting the crystalline forms
CN101679218B (en) Crystalline minocycline base and processes for its preparation
WO2019245091A1 (en) Method for preparing lithium difluorophosphate crystal with high purity, and non-aqueous electrolyte solution for secondary battery using same
WO2020197190A1 (en) Method for preparing biocompatible polymer-based apixaban-loaded microspheres
WO2010030132A2 (en) Purification method for adefovir dipivoxil
WO2016117814A2 (en) Novel crystal form of benzimidazole derivative and preparation method thereof
WO2011144021A1 (en) Cefpiramide sodium hydrate, preparation method and uses thereof
WO2017023020A1 (en) Method of manufacturing improved ertapenem injection
WO2020242234A1 (en) Injectable composition containing prodrug of caspase inhibitors, and preparation method therefor
KR20030059812A (en) Process for the preparation of crystalline n-formimidoyl thienamycin monohydrate(imipenem monohydrate)
WO2011118929A2 (en) Novel crystal forms of epirubicin hydrochloride
WO2011141004A1 (en) Cefodizime sodium hydrate, preparation method and uses thereof
WO2020040474A1 (en) Method for preparing preparation containing sitagliptin immediate release layer, preparation prepared by preparation method, method for coating sitagliptin immediate release layer, and composition for coating sitagliptin immediate release layer
WO2018124803A1 (en) Method for preparing l-methionine crystals using crystallization technique
WO2022103239A1 (en) Preparation method for edoxaban tosylate or hydrate thereof
WO2020204624A1 (en) Mirabegron prodrug compound, and pharmaceutical use of same for treating or improving overactive bladder disease
WO2020159343A1 (en) Pharmaceutical composition for treating or preventing middle east respiratory syndrome
WO2016048058A1 (en) Method for preparing racemic or optically active d- or l-α―glycerophosphoryl choline solids
WO2017018816A1 (en) Pharmaceutical composition with improved storage stability and method for preparing the same
WO2021230561A1 (en) Crystalline salt of eribulin
WO2011013992A2 (en) R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and l-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial
WO2018016795A1 (en) Orotate of antiviral drug, preparation method therefor, and pharmaceutical composition containing orotate
WO2024025393A1 (en) Novel salt of imidazo[1,2-a]pyridine compound, crystalline form thereof, and preparation method
WO2019124674A1 (en) N-substituted maleimide purification method
EP0627431B1 (en) Process for preparing crystalline loracarbef monohydrate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16833256

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16833256

Country of ref document: EP

Kind code of ref document: A1